Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aimee Jackson

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
British Journal of Haematology|August 3, 2022
Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study)Alexander Sternberg, Rebecca Boucher, Helen Chantal Coulthard, et al.
American Journal of Obstetrics and Gynecology|September 13, 2012
Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestationSteve N Caritis, Shringi Sharma, Raman Venkataramanan, et al.
Journal of Leukocyte Biology|June 18, 2026
The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase II single arm, open label trialCarmela De Santo, Aimee Jackson, Francis Mussai, et al.
BMC Cancer|March 26, 2024
Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trialGraham McIlroy, Siân Lax, Charlotte Gaskell, et al.
BMC Cancer|November 15, 2022
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trialRichard Dillon, Shanna Maycock, Aimee Jackson, et al.
Blood Advances|April 14, 2023
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDSJustin Loke, Nicholas McCarthy, Aimee Jackson, et al.
Blood|April 21, 2024
Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trialSridhar Chaganti, Shanna Maycock, Graham McIlroy, et al.
British Journal of Clinical Pharmacology|November 28, 2022
The effect of TRV027 on coagulation in COVID-19: A pilot randomized, placebo-controlled trialAlexander J Robbins, Nur Amalina Che Bakri, Edward Toke-Bjolgerud, et al.
Leukemia Research|November 13, 2024
COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experienceGiovanna Lucchini, Elena Cozma, Aimee Jackson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2020
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid LeukemiaCharles Craddock, Aimee Jackson, Justin Loke, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|August 3, 2022
Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study)Alexander Sternberg, Rebecca Boucher, Helen Chantal Coulthard, et al.
American Journal of Obstetrics and Gynecology|September 13, 2012
Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestationSteve N Caritis, Shringi Sharma, Raman Venkataramanan, et al.
Journal of Leukocyte Biology|June 18, 2026
The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase II single arm, open label trialCarmela De Santo, Aimee Jackson, Francis Mussai, et al.
BMC Cancer|March 26, 2024
Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trialGraham McIlroy, Siân Lax, Charlotte Gaskell, et al.
BMC Cancer|November 15, 2022
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trialRichard Dillon, Shanna Maycock, Aimee Jackson, et al.
Blood Advances|April 14, 2023
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDSJustin Loke, Nicholas McCarthy, Aimee Jackson, et al.
Blood|April 21, 2024
Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trialSridhar Chaganti, Shanna Maycock, Graham McIlroy, et al.
British Journal of Clinical Pharmacology|November 28, 2022
The effect of TRV027 on coagulation in COVID-19: A pilot randomized, placebo-controlled trialAlexander J Robbins, Nur Amalina Che Bakri, Edward Toke-Bjolgerud, et al.
Leukemia Research|November 13, 2024
COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experienceGiovanna Lucchini, Elena Cozma, Aimee Jackson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2020
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid LeukemiaCharles Craddock, Aimee Jackson, Justin Loke, et al.
Pageof 3